Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

NCT07029828 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07029828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07029828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Recruiting
Start date
September 10, 2025
Completion date
June 26, 2030
Enrollment
140 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

severe alopecia areata